Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer.

Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. J Thorac Oncol. 2010 Mar; 5(3):354-60.

View in: PubMed

subject areas

Adenocarcinoma
Aged
Aged, 80 and over
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Carboplatin
Carcinoma, Large Cell
Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell
Cohort Studies
Female
Humans
Indoles
Lung Neoplasms
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Paclitaxel
Prognosis
Pyrroles
Safety
Survival Rate

authors with profiles

Mark Kozloff